taletrectinib + carboplatin + pemetrexed

A combination therapy comprising **taletrectinib**, **carboplatin**, and **pemetrexed**. - **Taletrectinib** is a small molecule inhibitor of the tyrosine kinase domain of ROS1 and NTRK, being developed primarily for the treatment of ROS1-positive non-small cell lung cancer (NSCLC). Its mechanism involves selective inhibition of oncogenic ROS1 and NTRK kinases, blocking downstream signaling associated with tumor growth and survival. - **Carboplatin** is a platinum-based chemotherapeutic agent that causes DNA crosslinking and strand breaks, leading to apoptosis in rapidly dividing tumor cells[3]. - **Pemetrexed** is an antifolate antineoplastic agent that inhibits several enzymes involved in folate metabolism and DNA synthesis, disrupting nucleotide synthesis and cell division[3]. This triple combination is under investigation for advanced or metastatic NSCLC with relevant oncogenic drivers.